• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

2022 Fiscal Year Final Research Report

ROCK inhibitor for treating intraocular fibrosis by modulating epithelial-to-mesenchymal transition.

Research Project

  • PDF
Project/Area Number 20K09828
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Review Section Basic Section 56060:Ophthalmology-related
Research InstitutionKyushu University

Principal Investigator

Ishikawa Keijiro  九州大学, 医学研究院, 助教 (00795304)

Co-Investigator(Kenkyū-buntansha) 松永 直哉  九州大学, 薬学研究院, 教授 (10432915)
武田 篤信  九州大学, 医学研究院, 准教授 (40560313)
中尾 新太郎  独立行政法人国立病院機構九州医療センター(臨床研究センター), その他部局等, 客員研究員 (50583027)
村上 祐介  九州大学, 大学病院, 講師 (50634995)
Project Period (FY) 2020-04-01 – 2023-03-31
Keywords網膜症 / 糖尿病網膜症 / 網膜剥離 / 形質転換 / リポソーム
Outline of Final Research Achievements

In this study, the pharmacodynamic properties of liposome-encapsulated ROCK inhibitors were investigated in different animal models. The liposome encapsulation showed significantly improved retention in the eye compared to the non-liposome drug. In addition, in the study of the inhibitory effect on intraocular fibroproliferation, the liposome-encapsulated ROCK inhibitor was found to be effective for a long period of time with fewer intraocular administrations. In addition, the intraocular expression of periostin, a biomarker that reflects intraocular fibrosis, was also significantly suppressed by the liposomal formulation.

Free Research Field

眼科学

Academic Significance and Societal Importance of the Research Achievements

眼内線維増殖に対する薬剤は、未だ臨床応用されておらず新規治療薬開発が望まれている。今回の研究成果により、眼内線維増殖抑制が期待されるROCK阻害薬の臨床応用に向けて、リポソーム化修飾することで、頻回の眼内注射を避けることができる可能性が示された。

URL: 

Published: 2024-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi